---

Article 1 — Merino et al. | Single-cell analysis of the progeria arterial wall

PMID: 42538566 | Genome Medicine | Aging/Longevity | Triage Score: 9

Dimension	Score	Rationale
Scientific Novelty	9	First single-cell atlas of HGPS arterial disease; reveals cell-type-specific dysfunction and somatic mutation accumulation simultaneously — landmark resource
Clinical Relevance	3	Animal model; no immediate clinical translation, but mechanistic insights directly relevant to normal vascular aging biology
Population Reach	5	HGPS itself is ultra-rare (~400 patients worldwide), but aging niche programs have broad relevance to the general population's cardiovascular aging
Implementation Speed	2	Lab-stage discovery; 10+ years to therapeutic application
Evidence Strength	7	Genome Medicine peer-reviewed; scRNA-seq is a rigorous, systematic approach; single-species model is the main limitation

Key quantitative result: Cell-type-specific progerin-induced dysfunction characterized with somatic mutation accumulation demonstrated at single-cell resolution. External validation: Not independently replicated; landmark atlas study design typically precedes replication. Main limitation: Animal model (likely mouse or HGPS model organism); no human arterial single-cell validation; no therapeutic intervention tested. Equity implications: HGPS affects children of all backgrounds; insights into normal vascular aging could ultimately benefit populations with disparate cardiovascular disease burden (e.g., Black Americans with higher CVD mortality). Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (3×0.30) + (5×0.25) + (9×0.20) + (2×0.15) + (7×0.10) = 0.90 + 1.25 + 1.80 + 0.30 + 0.70 = 4.95

---

Article 2 — Liao et al. | Targeting ACSF2 overcomes Ara-C resistance in AML

PMID: 42538429 | Leukemia | Hematologic Malignancies | Triage Score: 8

Dimension	Score	Rationale
Scientific Novelty	8	ACSF2 as a novel metabolic target linking cholesterol esterification to cytarabine resistance is not previously described; novel mechanism in R/R AML
Clinical Relevance	4	Mixed (in vitro + in vivo); fatostatin is not yet a clinical agent; addresses a critical unmet need (Ara-C resistance) but no human data
Population Reach	6	AML affects ~20,000 new patients/year in the US; R/R AML has very poor prognosis; globally significant
Implementation Speed	3	Preclinical stage; fatostatin needs IND-enabling studies; 5–10 years minimum to clinical trial
Evidence Strength	6	Leukemia (top-tier journal); in vitro + in vivo validation; mechanistic rigor; abstract only limits full assessment

Key quantitative result: SREBF1 inhibitor fatostatin + Ara-C synergy demonstrated in resistant AML in vitro and in vivo; specific effect sizes not extractable from abstract. External validation: Not independently replicated; in vivo xenograft provides partial validation. Main limitation: Preclinical only; abstract access only; fatostatin not clinically approved; translation pathway unclear. Equity implications: AML disproportionately affects older adults and has worse outcomes in Black patients; a resistance-overcoming strategy could benefit underserved populations if access is equitable. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (6×0.25) + (8×0.20) + (3×0.15) + (6×0.10) = 1.20 + 1.50 + 1.60 + 0.45 + 0.60 = 5.35

---

Article 3 — Zhao et al. | Low-dose bevacizumab + atezolizumab enhances TACE in HCC

PMID: 42537705 | J Hepatol | Novel Therapeutics | Triage Score: 8

Dimension	Score	Rationale
Scientific Novelty	7	PDGFC+ TAM-mediated pericyte-to-fibroblast transition as a TACE-induced dysfunction mechanism is novel; mechanistic explanation for combination benefit is new
Clinical Relevance	7	Multi-cohort validation + retrospective clinical data; low-dose bev+ate combination uses already-approved agents; directly actionable for clinical trial design
Population Reach	7	HCC is the 6th most common cancer globally; ~900,000 new cases/year; TACE is the most widely used locoregional treatment worldwide
Implementation Speed	6	Both agents are approved; retrospective clinical data exist; trial registration plausible in 1–3 years; regulatory pathway needs prospective RCT
Evidence Strength	7	J Hepatol top-tier; snRNA-seq + multi-cohort + retrospective clinical — three-pronged approach adds credibility; retrospective design and abstract-only access are limitations

Key quantitative result: Improved clinical outcomes after TACE in retrospective cohort (specific HR/ORR not extractable from abstract). External validation: Multi-cohort validation is partial external validation; prospective RCT not yet done. Main limitation: Retrospective clinical component; mechanistic claims from snRNA-seq require prospective validation; abstract only. Equity implications: HCC disproportionately affects people with hepatitis B/C (prevalent in sub-Saharan Africa, East/Southeast Asia); if this strategy is affordable and accessible in resource-limited settings it could have major global equity impact — but bevacizumab + atezolizumab combination costs remain high. Evidence Maturity: Validated — with caveat that "validated" applies to multi-cohort mechanistic data; clinical evidence remains retrospective → Partially Validated / Potentially Practice-Changing (upgrade from Phase 1 classification is warranted given J Hepatol + multi-cohort design)

Phase 2 Composite Score: (7×0.30) + (7×0.25) + (7×0.20) + (6×0.15) + (7×0.10) = 2.10 + 1.75 + 1.40 + 0.90 + 0.70 = 6.85

---

Article 4 — Chen et al. | Acetate uptake in endothelial cells promotes HCC angiogenesis

PMID: 42538152 | Gut | Novel Therapeutics | Triage Score: 8

Dimension	Score	Rationale
Scientific Novelty	8	MCT1/ACSS2-mediated H3K27ac epigenetic reprogramming in tumor endothelial cells as a metabolic-immune axis in HCC is a genuinely new mechanism
Clinical Relevance	4	Multiple mouse models + human samples; non-human primary; ACSS2 inhibitors not yet in clinical HCC trials
Population Reach	7	HCC global burden same as Article 3; dual relevance to angiogenesis and immunotherapy resistance
Implementation Speed	3	Preclinical; ACSS2 inhibitor development needed; 5–10 years
Evidence Strength	6	Gut top-tier; multiple mouse models + human samples add rigor; abstract only

Key quantitative result: ACSS2 inhibition + anti-PD-1 synergy demonstrated in HCC models; specific effect sizes not available from abstract. External validation: Not independently replicated. Main limitation: Entirely preclinical; no approved ACSS2 inhibitor; abstract only. Equity implications: Same as Article 3 — HCC global burden skewed toward lower-income countries where ACSS2-targeted therapies would be inaccessible in the near term. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (8×0.20) + (3×0.15) + (6×0.10) = 1.20 + 1.75 + 1.60 + 0.45 + 0.60 = 5.60

---

Article 5 — Tsugaru et al. | D-serine as a metabolic immune checkpoint

PMID: 42538270 | EBioMedicine | Novel Therapeutics | Triage Score: 8

Dimension	Score	Rationale
Scientific Novelty	9	D-amino acids as immune checkpoint metabolites is an entirely novel class; D-serine's role in the tumor microenvironment has not been previously described as a therapeutic axis
Clinical Relevance	4	Translational (scRNA-seq + organoids + microbiome + clinical correlates); clinical data are correlative only
Population Reach	7	GI cancers (colorectal, gastric, esophageal) collectively represent one of the largest cancer burdens globally
Implementation Speed	3	Preclinical; mechanism requires clinical validation; microbiome-targeting adds complexity; 5–10 years
Evidence Strength	6	EBioMedicine high-impact; multi-modal validation including organoid allografts and microbiome manipulation; medium classification confidence slightly reduces score

Key quantitative result: Clinical correlates in GI cancer patients support tumor microenvironment relevance; specific ORR or effect sizes not specified in abstract. External validation: Not independently replicated; multi-modal study design provides internal validation breadth. Main limitation: Preclinical; mechanism connecting D-serine, macrophages, and T cells requires further delineation; medium classification confidence. Equity implications: GI cancers affect diverse global populations; D-serine modulation through dietary or microbiome-targeted approaches could eventually be low-cost, but therapeutic development pathway is uncertain. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (9×0.20) + (3×0.15) + (6×0.10) = 1.20 + 1.75 + 1.80 + 0.45 + 0.60 = 5.80

---

Article 6 — Zhao et al. | MYC rearrangement improves double-hit model in MM

PMID: 42537584 | ESMO Open | Hematologic Malignancies | Triage Score: 7

Dimension	Score	Rationale
Scientific Novelty	6	MYC-R as a prognostic factor in MM is known; the incremental value (C-index 0.549→0.581) and IgH/MYC fusion's worst-prognosis identification are moderately novel additions
Clinical Relevance	7	Prospective cohort from a clinical trial; FISH panel integration is immediately actionable; directly informs treatment stratification
Population Reach	6	Multiple myeloma: ~35,000 new cases/year in the US; globally significant; a sizeable subpopulation with MYC-R
Implementation Speed	7	FISH testing for MYC-R is technically feasible now; incremental C-index improvement is modest but meaningful; guideline adoption possible within 2–3 years
Evidence Strength	7	Prospective cohort from named clinical trial (NICHE, NCT04645199); HR 1.96 with p=0.007; human data

Key quantitative result: HR 1.96 (p=0.007) for PFS; C-index improvement 0.549→0.581; IgH/MYC fusion worst outcomes. External validation: Not externally replicated in this report; prospective trial design is high-quality single-cohort validation. Main limitation: Modest C-index improvement; not yet validated in independent cohorts; sample size not specified. Equity implications: Access to FISH testing for MYC-R rearrangement varies significantly by institution and geography; implementation may widen care gaps in low-resource settings. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (6×0.20) + (7×0.15) + (7×0.10) = 2.10 + 1.50 + 1.20 + 1.05 + 0.70 = 6.55

---

Article 7 — Rachamala et al. | AI-driven GIPC1 PDZ inhibitor for PDAC

PMID: 42537645 | Cell Reports | Precision Oncology | Triage Score: 7

Dimension	Score	Rationale
Scientific Novelty	8	"Undruggable" PDZ domain successfully targeted by AI-driven small molecule discovery; HDX-MS binding confirmation is methodologically rigorous
Clinical Relevance	4	Patient-derived organoids and xenografts are strong preclinical models but no human clinical data; PDAC's extremely poor prognosis amplifies relevance
Population Reach	5	PDAC: ~65,000 new US cases/year; <13% 5-year survival; extremely high unmet need
Implementation Speed	3	IND-enabling studies and Phase I trials are years away; novel target with no existing clinical data
Evidence Strength	6	Cell Reports; AI + HDX-MS + PDO + xenograft is multi-modal; medium classification confidence; no human data

Key quantitative result: GIPCi alone or with gemcitabine significantly suppresses PDAC tumor growth and improves survival in PDO and xenograft models; specific effect sizes not reported in available metadata. External validation: Not independently replicated; PDO models provide patient-derived validation. Main limitation: Entirely preclinical; GIPC1 biology in humans not fully characterized; medium confidence. Equity implications: PDAC has significant racial disparities (higher incidence and mortality in Black Americans); a novel targeted therapy could help, but access and cost remain concerns. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (8×0.20) + (3×0.15) + (6×0.10) = 1.20 + 1.25 + 1.60 + 0.45 + 0.60 = 5.10

---

Article 8 — Zhang et al. | CPNE1 promotes CAR-T resistance in HCC

PMID: 42538053 | J Immunother Cancer | Novel Therapeutics | Triage Score: 7

Dimension	Score	Rationale
Scientific Novelty	7	CPNE1 as a novel CAR-T resistance node via STAT3-TGF-β in solid tumors is new; clinical correlation with ICI outcomes adds translational value
Clinical Relevance	4	Mixed (in vitro + in vivo + clinical correlates); CAR-T in HCC is not yet standard of care; mechanism is actionable but requires clinical validation
Population Reach	6	HCC global burden is large; solid tumor CAR-T is a rapidly growing field
Implementation Speed	3	CPNE1 knockdown strategies (RNAi, etc.) are preclinical; 5–10 years
Evidence Strength	6	J Immunother Cancer premier journal; in vitro + in vivo + clinical correlate is well-rounded; no human interventional data

Key quantitative result: CPNE1 knockdown restores GPC3 CAR-T function with enhanced intratumoral infiltration and no systemic toxicity; specific effect sizes not available. External validation: Clinical correlate data provides partial external validity. Main limitation: Preclinical; GPC3-targeted CAR-T for HCC not yet approved; mechanism of CPNE1 knockdown delivery not specified. Equity implications: HCC highest in Asia and sub-Saharan Africa; CAR-T access is very limited in these regions, creating an equity gap. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (6×0.25) + (7×0.20) + (3×0.15) + (6×0.10) = 1.20 + 1.50 + 1.40 + 0.45 + 0.60 = 5.15

---

Article 9 — Talor et al. | Neoadjuvant immunotherapy in PD-L1-low OSCC (IT-MATTERS)

PMID: 42537452 | Oral Oncology | Novel Therapeutics | Triage Score: 7

Dimension	Score	Rationale
Scientific Novelty	7	Effective neoadjuvant immunotherapy in PD-L1-low OSCC is counterintuitive and highly novel; LI+CIZ combination not widely known
Clinical Relevance	8	Phase 3 RCT; 5-year OS data; HR 0.26 with 32% absolute survival advantage is clinically striking; directly practice-informing if replicated
Population Reach	5	OSCC: ~54,000 new cases/year in US; globally prevalent especially in South/Southeast Asia where tobacco/betel nut use is high
Implementation Speed	6	Phase 3 completed; agents exist; regulatory review and independent validation needed; 2–5 years potentially
Evidence Strength	6	Phase 3 RCT is top design; however medium classification confidence; specific agents (LI+CIZ) not fully identified in metadata; sample size unknown; publication in Oral Oncology rather than higher-tier journal slightly reduces confidence

Key quantitative result: OS HR 0.26 (p=0.0023); PFS HR 0.43 (p=0.0178); 32% absolute survival advantage at 60 months in PD-L1 TPS <10% cN0 OSCC. External validation: Single trial; no independent replication yet. Main limitation: Medium classification confidence; LI+CIZ composition unclear; subgroup analysis (PD-L1-low) raises multiplicity concerns; requires independent replication. Equity implications: OSCC disproportionately affects lower-income populations (tobacco, alcohol, HPV, betel nut); a highly effective neoadjuvant regimen could benefit underserved populations if cost-accessible. Evidence Maturity: Validated — but requires independent replication before full practice change. → Potentially Practice-Changing (upgrade warranted given RCT design and effect size)

Phase 2 Composite Score: (8×0.30) + (5×0.25) + (7×0.20) + (6×0.15) + (6×0.10) = 2.40 + 1.25 + 1.40 + 0.90 + 0.60 = 6.55

---

Article 10 — Schoser B | Therapeutic corridor of stability in Pompe disease ERT

PMID: 42538546 | Orphanet J Rare Dis | Rare Diseases | Triage Score: 7

Dimension	Score	Rationale
Scientific Novelty	5	Synthesizes existing evidence into a novel quantitative framework; not a discovery per se but operationally new
Clinical Relevance	8	Immediately actionable; provides specific numerical thresholds for clinical decision-making in a disease with three approved ERTs and no prior consensus monitoring framework
Population Reach	4	Pompe disease: ~1/40,000 prevalence; rare but devastating; relative to the Pompe population, this is highly impactful
Implementation Speed	9	Systematic review + position statement = immediately citable by clinicians and guideline committees; no regulatory or trial barriers
Evidence Strength	7	Systematic review + evidence-based position statement; Orphanet JRDI premier rare disease journal; single expert authorship is a limitation

Key quantitative result: FVC alarm threshold >5% decline/12 months; 6MWT action threshold >25m decline from peak; uHex-4/CK as early surrogates. External validation: Synthesizes existing validated study data; not a new primary study. Main limitation: Single-author position statement; expert consensus has inherent subjectivity; thresholds need prospective validation. Equity implications: Pompe disease patients globally face limited ERT access; this framework helps optimize use of costly therapies and could inform switching decisions — potentially relevant to health economics in low-resource settings. Evidence Maturity: Validated ✓ (confirmed) → Potentially Practice-Changing within the rare disease context

Phase 2 Composite Score: (8×0.30) + (4×0.25) + (5×0.20) + (9×0.15) + (7×0.10) = 2.40 + 1.00 + 1.00 + 1.35 + 0.70 = 6.45

---

Article 11 — Frigault et al. | CRS/ICANS with axi-cel/brexu-cel — CIBMTR data

PMID: 42537846 | Transplant Cell Ther | Hematologic Malignancies | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	4	CRS and ICANS with axi-cel/brexu-cel are well-characterized; this adds real-world incidence benchmarking, which is incrementally valuable
Clinical Relevance	7	Largest real-world CIBMTR dataset (n=927, 87 centers); directly informs CAR-T toxicity management and prophylaxis practices
Population Reach	5	CAR-T recipients are a growing but still relatively small population; globally expanding
Implementation Speed	7	Data immediately usable for clinical practice benchmarking and institutional protocol development
Evidence Strength	7	CIBMTR registry is gold standard for real-world CAR-T data; 87 centers adds generalizability; retrospective design is a limitation

Key quantitative result: CRS 82.6% (grade≥2: 47%); ICANS 48.4% (grade≥2: 71.5%); most managed with tocilizumab; 49.8% received ICANS prophylaxis. External validation: Registry-based; confirms prescribing information incidence rates in real world. Main limitation: Retrospective; abstract only; management heterogeneity across 87 centers may obscure best-practice signals. Equity implications: CAR-T access remains concentrated in academic centers in high-income countries; real-world data from a broad network helps identify toxicity patterns that may disproportionately affect patients in lower-volume or less-resourced centers. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (7×0.30) + (5×0.25) + (4×0.20) + (7×0.15) + (7×0.10) = 2.10 + 1.25 + 0.80 + 1.05 + 0.70 = 5.90

---

Article 12 — Bashir et al. | Evomela for autologous transplant in myeloma

PMID: 42537695 | Blood Adv | Hematologic Malignancies | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	5	AUC-guided Evomela dosing is incrementally novel; confirms PK-outcome relationship in myeloma ASCT
Clinical Relevance	7	Bayesian-designed Phase I/II trial; 45% MRD-negative sCR/CR; directly informs conditioning regimen optimization for a standard procedure
Population Reach	6	Multiple myeloma ASCT: widely performed; ~8,000–10,000 ASCTs/year in US for MM
Implementation Speed	6	Evomela is FDA-approved; AUC-guided dosing framework could be adopted without new regulatory approval
Evidence Strength	7	Phase I/II Bayesian design from MD Anderson; posterior probability 0.99 for AUC-benefit association; propensity-matched comparison; full text available

Key quantitative result: 45% MRD-negative sCR/CR at day 90; posterior probability of higher AUC benefit = 0.99; improved PFS vs MEL200 in propensity-matched analysis. External validation: Propensity-matched comparison provides partial validation; not independently replicated. Main limitation: Single-center; propensity matching is observational; needs larger randomized confirmation. Equity implications: ASCT access is concentrated in specialized centers; AUC-guided dosing could improve outcomes for patients who do reach transplant centers, but doesn't address access inequities. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (5×0.20) + (6×0.15) + (7×0.10) = 2.10 + 1.50 + 1.00 + 0.90 + 0.70 = 6.20

---

Article 13 — Shin et al. | Serum ketone bodies and kidney/CV outcomes in T2DM

PMID: 42537913 | Diabetes Res Clin Pract | CV/Metabolic | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	6	Ketonemia as a biomarker and potential mediator of renoprotection in T2DM extends SGLT2i mechanistic data in a prospective cohort setting
Clinical Relevance	6	Prospective cohort; aHR 0.46 for eGFR decline is clinically meaningful; supports ketone-mediated renoprotection hypothesis
Population Reach	8	T2DM affects ~537 million people globally; diabetic kidney disease is a leading cause of ESRD
Implementation Speed	5	Biomarker data alone; not immediately actionable without therapeutic direction; may support dietary or SGLT2i monitoring applications
Evidence Strength	6	Prospective cohort is well-designed; aHR 0.46 (95% CI 0.26–0.84) is credible; abstract only; residual confounding likely

Key quantitative result: aHR 0.46 (95% CI 0.26–0.84) for ≥40% eGFR decline; aHR 0.63 for composite kidney outcomes. External validation: Not independently replicated in this study. Main limitation: Observational; residual confounding; cardiovascular endpoints non-significant; abstract only. Equity implications: T2DM disproportionately affects racial/ethnic minorities and lower-income populations; ketone monitoring applications could be low-cost if dietary approaches are validated. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (6×0.30) + (8×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 1.80 + 2.00 + 1.20 + 0.75 + 0.60 = 6.35

---

Article 14 — Rudran et al. | GLP-1 RAs improve outcomes after THA/TKA

PMID: 42538001 | Bone Joint J | CV/Metabolic | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	5	GLP-1RA perioperative benefit is becoming established; this is a confirmatory meta-analysis in orthopedic surgery specifically
Clinical Relevance	7	RR 0.73 for surgical complications; directly actionable for preoperative GLP-1RA management decisions in a massive surgical population
Population Reach	8	~1 million THA/TKAs/year in US; millions globally; growing GLP-1RA use means this affects a large and expanding population
Implementation Speed	7	GLP-1RAs are already prescribed to many surgical patients; this data can immediately inform perioperative management protocols
Evidence Strength	6	PRISMA systematic review + meta-analysis; medium classification confidence; pooled observational studies with inherent confounding

Key quantitative result: Surgical complications RR 0.73; medical complications RR 0.78; readmissions RR 0.79; THA surgical complications RR 0.63. External validation: Meta-analysis pools multiple studies; inherent heterogeneity in included studies. Main limitation: Underlying studies are predominantly observational; medium confidence; confounding by indication likely (GLP-1RA users may be healthier overall). Equity implications: GLP-1RA users skew toward higher-income, insured patients; perioperative benefits may not reach lower-income patients who cannot access these drugs. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (7×0.30) + (8×0.25) + (5×0.20) + (7×0.15) + (6×0.10) = 2.10 + 2.00 + 1.00 + 1.05 + 0.60 = 6.75

---

Article 15 — Nageswaran et al. | MASLD + Lp(a) and long-term CVD outcomes (MESA)

PMID: 42537842 | Metabolism | CV/Metabolic | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	6	First study combining MASLD-Lp(a) interaction with long-term CV outcomes; both biomarkers are individually well-studied; the intersection is novel
Clinical Relevance	6	HR 2.07 for hard CVD events is clinically significant; informs risk stratification but no direct therapeutic actionability yet
Population Reach	7	MASLD affects ~25% of adults globally; Lp(a) elevation affects ~20%; overlap is a large population
Implementation Speed	5	Lp(a) testing is not universally performed; Lp(a)-lowering agents are in late trials; combined risk stratification is actionable now but interventions are limited
Evidence Strength	6	MESA multi-ethnic prospective cohort is high quality; secondary analysis; abstract only

Key quantitative result: HR 2.07 for hard CVD events (MASLD + high Lp(a)); HR 1.28 for all-cause mortality (MASLD + low Lp(a)). External validation: MESA is a well-validated prospective cohort; secondary analysis. Main limitation: Secondary analysis; abstract only; residual confounding; no intervention data. Equity implications: MESA is multi-ethnic, which is a strength; MASLD and CVD disproportionately affect Hispanic and Black Americans; Lp(a)-lowering therapy access will be a future equity concern. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 1.80 + 1.75 + 1.20 + 0.75 + 0.60 = 6.10

---

Article 16 — Sato et al. | Urine cfDNA for IPMN diagnosis

PMID: 42536239 | Ann Surg Oncol | Early Cancer Detection | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	7	Urine cfDNA outperforming plasma cfDNA for IPMN mutation detection is a genuinely novel finding with clinical implications for non-invasive pancreatic surveillance
Clinical Relevance	6	Prospective with surgical pathology validation; OR 8.10 for malignancy is compelling; very small sample (n=33) limits current applicability
Population Reach	4	IPMN surveillance affects a growing but still modest population; pancreatic cancer prevention is a high-priority area
Implementation Speed	5	Urine cfDNA is technically feasible; needs much larger validation before clinical adoption
Evidence Strength	5	Prospective design is strong; n=33 is very small; medium classification confidence; abstract only

Key quantitative result: KRAS detected in 58% (vs 19% plasma); GNAS in 32% (vs 10% plasma); GNAS+KRAS positivity OR 8.10 (p=0.027) for malignancy. External validation: Not replicated; single-center prospective study. Main limitation: Very small n=33; single-center; medium confidence; needs validation in larger multi-center cohorts. Equity implications: Non-invasive urine testing could improve IPMN surveillance access in settings where endoscopic procedures are limited. Evidence Maturity: Validated — with strong caveats about sample size. → Exploratory-Validated (revise downward; n=33 makes "Validated" premature)

Phase 2 Composite Score: (6×0.30) + (4×0.25) + (7×0.20) + (5×0.15) + (5×0.10) = 1.80 + 1.00 + 1.40 + 0.75 + 0.50 = 5.45

---

Article 17 — Chen et al. | PhenoSS rare disease prediction

PMID: 42535932 | JAMIA | Rare Diseases | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	6	Gaussian copula modeling of HPO term dependencies is methodologically novel for rare disease phenotype matching
Clinical Relevance	5	EHR validation; clinically relevant for diagnostic decision support in rare disease; indirect patient impact
Population Reach	5	~300 million people live with rare diseases globally; diagnostic odyssey is a major problem; PhenoSS could reduce this
Implementation Speed	5	Computational tool; deployment requires EHR integration; 2–5 years for clinical adoption
Evidence Strength	6	JAMIA top-tier informatics journal; EHR validation adds clinical grounding; abstract only

Key quantitative result: PhenoSS outperforms existing methods in sparse/noisy HPO scenarios; specific AUC/accuracy metrics not available from abstract. External validation: Validated on real EHR data; not independently replicated. Main limitation: Performance details unclear; clinical utility not yet prospectively demonstrated; abstract only. Equity implications: Rare disease diagnostic odyssey is worse in lower-resource settings; a computational tool could democratize expert-level phenotype matching if deployed in EHRs broadly. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (5×0.30) + (5×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 1.50 + 1.25 + 1.20 + 0.75 + 0.60 = 5.30

---

Article 18 — Kulmala et al. | Childhood aplastic anemia — national cohort

PMID: 42533598 | Pediatr Blood Cancer | Rare Diseases | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	4	National incidence and outcomes data; largely confirmatory of known epidemiology; HRQoL sex differences are a notable finding
Clinical Relevance	5	Contemporary benchmark data; 41% IST-to-HSCT rate and female HRQoL deficit are clinically actionable for follow-up care planning
Population Reach	3	Very rare pediatric disease; incidence 2.9/million/year
Implementation Speed	7	HRQoL monitoring improvements are immediately implementable; data directly available for clinical benchmarking
Evidence Strength	7	National population-based cohort (Finland 2006–2020); comprehensive coverage; abstract only

Key quantitative result: OS 92.7%; 41% IST-treated severe AA progressed to HSCT; females reported worse HRQoL across multiple domains. External validation: National population-based data is inherently comprehensive for Finland; not replicated in other countries. Main limitation: Single-country dataset; abstract only; HRQoL tools not specified. Equity implications: Female sex as an at-risk group for worse HRQoL despite survival is an equity finding deserving targeted supportive care interventions. Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (5×0.30) + (3×0.25) + (4×0.20) + (7×0.15) + (7×0.10) = 1.50 + 0.75 + 0.80 + 1.05 + 0.70 = 4.80

---

Article 19 — Li et al. | EEG-based ML for sleep apnea detection

PMID: 42537009 | JMIR | AI/ML Diagnostics | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	5	EEG-based ML for sleep apnea builds on existing literature; first SR+MA on this specific modality adds incremental value
Clinical Relevance	5	Strong segment-level performance (AUROC 0.95); critically only 2 studies evaluated patient-level performance — major gap for clinical use
Population Reach	8	Sleep apnea affects ~1 billion people globally; massive unmet need for accessible diagnostics
Implementation Speed	5	EEG-based home monitoring is technically feasible; patient-level validation needed before deployment
Evidence Strength	6	PRISMA-DTA meta-analysis; JMIR high-impact; honest about limitations; heterogeneity across included studies likely

Key quantitative result: Pooled sensitivity 0.90, specificity 0.92, AUROC 0.95 (segment-level); only 2 studies with patient-level data. External validation: Meta-analysis of multiple studies provides pooled validation. Main limitation: Segment-level vs patient-level performance gap is a critical clinical translation barrier; only 2 patient-level studies. Equity implications: EEG-based home sleep apnea testing could expand access beyond sleep lab settings, potentially benefiting rural and underserved populations who currently have limited access to polysomnography. Evidence Maturity: Validated ✓ (confirmed) — at segment level; Exploratory at patient level

Phase 2 Composite Score: (5×0.30) + (8×0.25) + (5×0.20) + (5×0.15) + (6×0.10) = 1.50 + 2.00 + 1.00 + 0.75 + 0.60 = 5.85

---

Article 20 — Kebir et al. | TTFields before/during RT in GBM (PriCoTTF)

PMID: 42538542 | BMC Cancer | Sentinel | Triage Score: 6

Dimension	Score	Rationale
Scientific Novelty	5	Earlier TTFields initiation is an evolutionary refinement; the safety data are new and the feasibility in the RT-concurrent setting is novel for this phase
Clinical Relevance	6	Phase I/II multicenter; 0/20 protocol-limiting toxicities; median OS 18.0 months; directly supports randomized trial design
Population Reach	4	GBM: ~14,000 new cases/year in US; very poor prognosis; moderate population reach but extremely high unmet need
Implementation Speed	5	Safety established; randomized phase II/III needed; device availability and compliance are barriers; 5+ years
Evidence Strength	6	Multicenter phase I/II; n=20; small but adequately powered for safety endpoint; medium confidence

Key quantitative result: 0/20 protocol-limiting toxicities (exact 95% CI 0–16.8%); 76.5% median device usage; OS 18.0 months (95% CI 12.1–19.9). External validation: Not replicated; enables randomized evaluation. Main limitation: n=20; feasibility only; OS data are preliminary and uncontrolled; medium confidence. Equity implications: TTFields devices are expensive (~$21,000/month); access is highly limited outside high-income settings, creating a significant equity gap. Evidence Maturity: Validated ✓ (confirmed) — for safety/feasibility only

Phase 2 Composite Score: (6×0.30) + (4×0.25) + (5×0.20) + (5×0.15) + (6×0.10) = 1.80 + 1.00 + 1.00 + 0.75 + 0.60 = 5.15

---

Article 21 — Voran et al. | ESC cardio-oncology definitions in CAR-T patients

PMID: 42538564 | Cardiooncology | Hematologic Malignancies | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	5	First application of ESC 2022 definitions to CAR-T; fills a methodological gap; not a mechanistic discovery
Clinical Relevance	6	Standardizes cardiovascular monitoring framework for a growing patient population; n=104; directly implementable
Population Reach	4	CAR-T recipients are still a relatively small population globally
Implementation Speed	7	ESC definitions are published; application to CAR-T patients is immediately feasible; no regulatory barrier
Evidence Strength	5	Retrospective single-center; n=104; medium confidence; full text available

Key quantitative result: Incidence/severity/prognostic relevance of CTR-CVT characterized in 104 CAR-T patients using ESC 2022 definitions (specific rates not in metadata). External validation: Not replicated; single-center. Main limitation: Single-center retrospective; medium confidence; small n. Equity implications: CAR-T access concentrated in academic centers; standardized toxicity monitoring helps ensure patients at these centers receive consistent surveillance. Evidence Maturity: Validated ✓ (confirmed) — as a descriptive benchmark

Phase 2 Composite Score: (6×0.30) + (4×0.25) + (5×0.20) + (7×0.15) + (5×0.10) = 1.80 + 1.00 + 1.00 + 1.05 + 0.50 = 5.35

---

Article 22 — Zampieri et al. | Dapagliflozin in critically ill AKI patients

PMID: 42537430 | J Crit Care | CV/Metabolic | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	SGLT2i in AKI in the ICU is a genuinely underexplored and clinically important question; near-neutral profile is itself informative
Clinical Relevance	6	Directly addresses a safety concern that currently restricts SGLT2i use in AKI; results are reassuring but not conclusive
Population Reach	7	ICU-associated AKI is very common (~50% of ICU patients); SGLT2i expansion to this population would be highly impactful
Implementation Speed	5	Post-hoc from RCT; near-neutral results do not support immediate label change; larger powered RCT needed
Evidence Strength	6	RCT-derived post-hoc analysis (n=212 AKI subgroup); abstract only; underpowered for definitive conclusions

Key quantitative result: 28-day mortality 38% vs 40%; KRT 12% vs 18%; no excess hemodynamic/metabolic instability. External validation: Derived from DEFENDER RCT; subgroup analysis. Main limitation: Post-hoc; underpowered for subgroup; abstract only; cannot rule out moderate harm or benefit. Equity implications: AKI in the ICU disproportionately affects patients with comorbidities and limited prior care; safe SGLT2i use in this setting could benefit a broad, high-risk population. Evidence Maturity: Validated ✓ (confirmed) — but near-neutral; inconclusive

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 1.80 + 1.75 + 1.20 + 0.75 + 0.60 = 6.10

---

Article 23 — Mohammed et al. | SGLT-2i in resistant hypertension

PMID: 42538499 | High Blood Press Cardiovasc Prev | CV/Metabolic | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	5	SGLT-2i for resistant hypertension is an emerging area; ~3 mmHg SBP reduction provides a quantitative estimate in a specific high-need subgroup
Clinical Relevance	5	Clinically meaningful but effect size is modest (~3 mmHg); adverse event profile (volume depletion, hypotension, genital infections) requires consideration
Population Reach	6	Resistant/uncontrolled hypertension affects ~12–15% of hypertensive patients; a large subpopulation globally
Implementation Speed	5	SGLT-2is are approved; evidence base for resistant HTN is growing but not yet sufficient for guideline recommendation
Evidence Strength	5	Only 4 RCTs (n=3,718); "pilot" meta-analysis; medium confidence; modest effect size

Key quantitative result: SBP reduction ~3 mmHg; increased volume depletion, hypotension, and genital infections. External validation: Meta-analysis of 4 RCTs; limited by small number of trials. Main limitation: Only 4 RCTs; pilot designation indicates insufficient evidence for firm recommendations; medium confidence. Equity implications: Resistant hypertension disproportionately affects Black Americans and lower-income populations; SGLT-2i cost is a barrier to equitable access. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (5×0.20) + (5×0.15) + (5×0.10) = 1.50 + 1.50 + 1.00 + 0.75 + 0.50 = 5.25

---

Article 24 — Swillens et al. | Consensus requirements for CPath AI in CRC tumor budding

PMID: 42536993 | JCO CCI | AI/ML Diagnostics | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	5	Delphi consensus on AI adoption requirements is process innovation; not a scientific discovery; fills an important gap
Clinical Relevance	6	21/29 consensus requirements are directly actionable for AI algorithm developers and pathology departments; tumor budding is guideline-endorsed
Population Reach	7	Colorectal cancer: ~150,000 new US cases/year; global AI pathology deployment could reach millions
Implementation Speed	6	Framework is immediately publishable and citable; implementation across institutions requires governance and IT infrastructure
Evidence Strength	5	Delphi consensus (n=59 pathologists) is a methodologically appropriate design for this question; abstract only; 28% items without consensus is a limitation

Key quantitative result: 21/29 (72%) requirements achieved consensus; 8 (28%) without consensus. External validation: International expert panel provides distributed validation. Main limitation: Consensus does not equal evidence; 28% items unresolved; abstract only. Equity implications: AI pathology adoption may be concentrated in high-resource settings, widening the gap in CRC diagnostic quality between high- and low-income countries. Evidence Maturity: Validated ✓ (confirmed) — as expert consensus

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (5×0.20) + (6×0.15) + (5×0.10) = 1.80 + 1.75 + 1.00 + 0.90 + 0.50 = 5.95

---

Article 25 — Wang et al. | ML prediction of postoperative vomiting

PMID: 42536998 | JMIR Med Inform | AI/ML Diagnostics | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	5	LLM as normalization/explainability tool (not predictor) is a methodologically responsible and somewhat novel integration approach
Clinical Relevance	4	AUC 0.73 for POV prediction; useful but internal validation only; postoperative vomiting is important but not life-threatening
Population Reach	7	Millions of surgeries performed annually worldwide; PONV is nearly universal concern
Implementation Speed	5	Internal validation only; external validation needed before deployment; anti-leakage design is a strength
Evidence Strength	5	Large dataset (n=33,460); internal validation only; medium confidence; JMIR Medical Informatics

Key quantitative result: LightGBM AUC 0.729 pre-op, 0.735 end-of-surgery; vs Apfel score AUC 0.610. External validation: Internal validation only; major limitation. Main limitation: No external validation; LLM component adds methodological interest but not predictive power. Equity implications: Prediction models trained on single-center data may not generalize across diverse patient populations; explicit testing for demographic performance gaps not reported. Evidence Maturity: Validated ✓ (confirmed) — internally only

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (5×0.20) + (5×0.15) + (5×0.10) = 1.20 + 1.75 + 1.00 + 0.75 + 0.50 = 5.20

---

Article 26 — Wu et al. | Oxypeucedanin targets KIF11 in lung adenocarcinoma

PMID: 42537468 | Phytomedicine | Precision Oncology | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	TRIM21-mediated KIF11 ubiquitination is a mechanistically specific and novel pathway; natural compound with defined molecular target adds value
Clinical Relevance	3	Purely preclinical; natural compound clinical development path is long and uncertain
Population Reach	7	LUAD is most common lung cancer subtype; massive global burden
Implementation Speed	2	Preclinical; natural compound IND pathway is complex; 10+ years
Evidence Strength	5	In vitro + in vivo; medium confidence; Phytomedicine is a reasonable but not top-tier journal for oncology

Key quantitative result: KIF11 degradation → MCM2 destabilization → CDK1/Cyclin B1 downregulation → G2/M arrest and apoptosis demonstrated in vitro and in vivo. External validation: Not independently replicated. Main limitation: Natural compound; clinical development path unclear; abstract only; medium confidence. Equity implications: Natural compound extraction could be low-cost if clinical development succeeds, but the development pathway is very uncertain. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (3×0.30) + (7×0.25) + (6×0.20) + (2×0.15) + (5×0.10) = 0.90 + 1.75 + 1.20 + 0.30 + 0.50 = 4.65

---

Article 27 — Välimäki et al. | NRAS-mutant conjunctival melanoma precision therapy

PMID: 42537395 | Biomed Pharmacother | Precision Oncology | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	Ex vivo-to-clinical correlation in an ultra-rare cancer is methodologically notable; RAS(ON) inhibitor activity in this setting is new
Clinical Relevance	3	Single case; ultra-rare disease; n=1 evidence
Population Reach	2	Conjunctival melanoma: extremely rare (estimated ~0.5/million/year); very high relative unmet need within affected patients
Implementation Speed	3	MEK inhibitors exist clinically; ex vivo sensitivity testing platforms need development; medium timeline
Evidence Strength	3	Case report + ex vivo; n=1 clinical data; medium confidence; Biomed Pharmacother

Key quantitative result: MEK inhibitor and PARP inhibitor ex vivo efficacy; clinical MEK inhibitor produced "sustained benefit" (specific duration not specified). External validation: Not replicated. Main limitation: n=1; case report level evidence; cannot generalize; medium confidence. Equity implications: Ultra-rare cancer with no standard post-ICI treatment; even case-level evidence is important for this abandoned population. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (3×0.30) + (2×0.25) + (6×0.20) + (3×0.15) + (3×0.10) = 0.90 + 0.50 + 1.20 + 0.45 + 0.30 = 3.35

---

Article 28 — Kabirian et al. | ICI rechallenge in cervical/endometrial cancer (RICE)

PMID: 42538280 | Int J Gynecol Cancer | Novel Therapeutics | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	First multicenter evidence for ICI rechallenge in gynecologic cancers; 52% ORR at rechallenge is clinically notable
Clinical Relevance	6	52% ORR at rechallenge; 13% discontinuation for toxicity; directly applicable to clinical decision-making for post-ICI progression management
Population Reach	5	Cervical and endometrial cancers: ~90,000 new US cases combined/year; globally significant burden
Implementation Speed	6	ICIs are approved in these settings; rechallenge is technically feasible now; retrospective data supports a prospective trial
Evidence Strength	5	Multicenter (10 French centers); retrospective; medium confidence; abstract only

Key quantitative result: Rechallenge ORR 52%, median PFS 6.0 months; prior ICI exposure ORR 76%, median PFS 11.0 months; 13% discontinued for toxicity. External validation: Multicenter retrospective provides some breadth; not independently replicated. Main limitation: Retrospective; medium confidence; abstract only; selection bias in rechallenge decisions. Equity implications: Cervical cancer disproportionately affects lower-income women globally; ICI rechallenge data is relevant but access remains a major barrier. Evidence Maturity: Validated ✓ (confirmed) — retrospective

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (6×0.20) + (6×0.15) + (5×0.10) = 1.80 + 1.25 + 1.20 + 0.90 + 0.50 = 5.65

---

Article 29 — Li Y | Cross-species cardiac aging niche score (CCANS)

PMID: 42538413 | Funct Integr Genomics | Aging/Longevity | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	CCANS as a conserved aging program distinct from inflammatory fibroblast heterogeneity is a potentially important conceptual distinction
Clinical Relevance	3	Computational reanalysis; no therapeutic intervention; distant from clinical application
Population Reach	7	Heart failure affects ~64 million people globally; aging is universal
Implementation Speed	3	Purely computational; requires biological validation; 5–10+ years
Evidence Strength	5	Two independent human cohorts validated CCANS; single-author is a concern; Hedges g=1.04 is a large effect; medium confidence

Key quantitative result: CCANS Hedges g=1.04 (p=6.32×10⁻⁵) elevated in two independent heart failure cohorts. External validation: Two independent human cohorts provide cross-validation; single author limits rigor confidence. Main limitation: Single-author study; computational reanalysis; biological mechanism not experimentally validated; abstract only. Equity implications: Heart failure disproportionately affects lower-income and minority populations; if CCANS leads to therapeutic targets, equity of access will matter. Evidence Maturity: Validated ✓ (confirmed) — statistically, but requires independent replication and biological validation

Phase 2 Composite Score: (3×0.30) + (7×0.25) + (6×0.20) + (3×0.15) + (5×0.10) = 0.90 + 1.75 + 1.20 + 0.45 + 0.50 = 4.80

---

Article 30 — Manzoni et al. | Hidden multistate models for multimorbidity trajectories

PMID: 42538330 | Sci Rep | Aging/Longevity | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	Continuous-time hidden multistate models for multimorbidity is a methodological advance; bias reduction vs non-hidden models is the key finding
Clinical Relevance	4	Methodological paper; indirect clinical relevance via improved risk prediction
Population Reach	7	Multimorbidity affects the majority of older adults globally; aging population growth makes this increasingly important
Implementation Speed	4	Statistical methodology; requires clinical implementation before patient benefit
Evidence Strength	6	18-year SNAC-K cohort (n=2,716); well-established Swedish aging cohort; full text available

Key quantitative result: CCANS substantially reduces bias in hazard estimation vs non-hidden models; mortality gradient across latent multimorbidity patterns identified. External validation: SNAC-K is a validated established cohort. Main limitation: Methodological paper; indirect patient benefit; implementation in clinical systems not demonstrated. Equity implications: Better multimorbidity modeling could improve geriatric care allocation; most relevant to healthcare systems with rich longitudinal data (primarily high-income countries). Evidence Maturity: Validated ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (6×0.20) + (4×0.15) + (6×0.10) = 1.20 + 1.75 + 1.20 + 0.60 + 0.60 = 5.35

---

Article 31 — Shamsabadi et al. | LLMs vs EM physicians in diagnostic reasoning

PMID: 42538544 | Int J Emerg Med | AI/ML Diagnostics | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	5	LLM vs physician diagnostic comparison is a rapidly crowded space; testing GPT-5.2, Gemini 3, Claude Opus 4.1 with current models adds some currency
Clinical Relevance	4	Vignette-based only; not real patient data; 10 cases is far too small for clinical conclusions
Population Reach	8	Emergency medicine handles millions of patients annually; AI decision support would have massive reach if validated
Implementation Speed	4	Requires external validation, regulatory clearance, workflow integration; medium-term
Evidence Strength	3	Only 10 vignettes, 14 evaluators; "preliminary" by author's own designation; medium confidence

Key quantitative result: LLMs 73.75% vs physicians 57.0% (p=0.014) overall diagnostic accuracy; physicians' differential accuracy 45% vs LLMs' 69%. External validation: None; single preliminary study. Main limitation: Critically underpowered; 10 vignettes cannot support broad conclusions; vignette accuracy ≠ real-world clinical performance; medium confidence. Equity implications: AI decision support could improve emergency care quality in resource-limited settings if reliably validated; risk of overreliance on AI without adequate validation could harm patients in low-supervision settings. Evidence Maturity: "Validated" classification is inappropriate for 10-vignette study → Exploratory (revise)

Phase 2 Composite Score: (4×0.30) + (8×0.25) + (5×0.20) + (4×0.15) + (3×0.10) = 1.20 + 2.00 + 1.00 + 0.60 + 0.30 = 5.10

---

Article 32 — Numan et al. | NMP preserves endothelial clearance in liver grafts

PMID: 42538579 | Transplantation | Sentinel | Triage Score: 5

Dimension	Score	Rationale
Scientific Novelty	6	Mechanistic characterization of endothelial clearance preservation by NMP during warm ischemia is a specific and novel finding
Clinical Relevance	5	NMP is increasingly used; mechanistic data supports its expanded application to marginal donor livers; mixed design
Population Reach	4	Liver transplant: ~9,000/year in US; limited by organ availability; marginal donor expansion could increase numbers
Implementation Speed	5	NMP is an established technique; mechanistic evidence supports but doesn't require new regulatory approval
Evidence Strength	5	Ex vivo + clinical observational; mixed design; medium confidence; Transplantation top journal; abstract only

Key quantitative result: NMP preserves endothelial clearance and modulates inflammatory response during prolonged warm ischemia (specific metrics not available from abstract). External validation: Not replicated. Main limitation: Mixed design; abstract only; medium confidence; small clinical observational component. Equity implications: Organ shortage disproportionately harms minority patients on transplant waitlists; expanding use of marginal donor livers via NMP could reduce waiting times for disadvantaged groups. Evidence Maturity: Validated ✓ (confirmed) — mechanistically

Phase 2 Composite Score: (5×0.30) + (4×0.25) + (6×0.20) + (5×0.15) + (5×0.10) = 1.50 + 1.00 + 1.20 + 0.75 + 0.50 = 4.95

---

Article 33 — Liu et al. | MD-Mamba for breast cancer histopathology

PMID: 42537429 | Transl Oncol | AI/ML Diagnostics | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	4	Mamba state-space architecture for histopathology is an incremental architectural contribution; no major biological discovery
Clinical Relevance	3	Single-dataset benchmark only; no external validation; errors at Normal-Benign boundary are clinically concerning
Population Reach	7	Breast cancer is the most common cancer globally; histopathology AI has massive potential reach
Implementation Speed	3	External multi-institutional validation required before any clinical deployment
Evidence Strength	4	Single dataset (BACH 2018); no external validation; abstract only; high AUC on single dataset is insufficient

Key quantitative result: Accuracy 0.9625, AUC 0.9956 on BACH 2018 dataset; errors at Normal-Benign boundary. External validation: None. Main limitation: Single dataset; no external or whole-slide validation; Normal-Benign errors clinically significant. Equity implications: If validated and deployed, AI histopathology could improve breast cancer diagnosis quality in settings with limited pathologist availability. Evidence Maturity: "Validated" classification is overstated for single-dataset benchmark → Exploratory (revise)

Phase 2 Composite Score: (3×0.30) + (7×0.25) + (4×0.20) + (3×0.15) + (4×0.10) = 0.90 + 1.75 + 0.80 + 0.45 + 0.40 = 4.30

---

Article 34 — Lin et al. | MTM-based exercise in lymphoma during chemotherapy

PMID: 42538450 | J Cancer Surviv | Hematologic Malignancies | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	3	Exercise benefits during cancer treatment are well-established; this confirms benefit in lymphoma specifically during chemotherapy with a theory-based framework
Clinical Relevance	6	RCT; all p<0.001 for cognition, fitness, QoL; high adherence (79%); directly implementable
Population Reach	5	Lymphoma: ~90,000 new US cases/year; exercise programs are scalable
Implementation Speed	8	No regulatory barriers; exercise programs can be implemented immediately
Evidence Strength	6	RCT n=86; single-center; abstract only; well-designed but limited generalizability

Key quantitative result: Significant improvements in cognitive function, physical fitness, and QoL (all p<0.001); 79.0% adherence. External validation: Not replicated; single-center RCT. Main limitation: Single-center; small n=86; abstract only; long-term follow-up not reported. Equity implications: Exercise programs are low-cost; potentially accessible across income levels; however, structured programs require healthcare infrastructure and supervision. Evidence Maturity: Validated ✓ (confirmed) — within its scope

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (3×0.20) + (8×0.15) + (6×0.10) = 1.80 + 1.25 + 0.60 + 1.20 + 0.60 = 5.45

---

Article 35 — Gong et al. | Castleman disease case series

PMID: 42534895 | Front Oncol | Rare Diseases | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	2	Descriptive case series; no novel mechanistic or therapeutic insight
Clinical Relevance	3	n=12; descriptive only; limited actionability
Population Reach	2	Castleman disease: extremely rare
Implementation Speed	4	Descriptive data; immediate reference value for clinicians facing this disease
Evidence Strength	3	Retrospective case series n=12; lowest evidentiary tier

Key quantitative result: Descriptive clinical, pathological, and treatment outcome characterization across 12 cases. External validation: None. Main limitation: n=12; retrospective; descriptive only; Frontiers in Oncology. Equity implications: Rare disease documentation is important for all affected patients regardless of setting. Evidence Maturity: Validated — only in the limited sense of case documentation

Phase 2 Composite Score: (3×0.30) + (2×0.25) + (2×0.20) + (4×0.15) + (3×0.10) = 0.90 + 0.50 + 0.40 + 0.60 + 0.30 = 2.70

---

Article 36 — Xu et al. | Clinical pharmacology in rare disease development

PMID: 42535720 | J Clin Pharmacol | Rare Diseases | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	3	Review of known methodological approaches; no original data
Clinical Relevance	4	Useful for drug developers and regulators; indirect clinical impact
Population Reach	5	Rare diseases collectively affect 300 million globally
Implementation Speed	5	Methodological guidance is immediately applicable to drug development programs
Evidence Strength	2	Narrative review; no original data; abstract only

Key quantitative result: No primary quantitative result; synthesis of methodological approaches. External validation: N/A. Main limitation: Narrative review; no original data; abstract only. Equity implications: Bayesian and adaptive designs could accelerate drug approval for neglected rare diseases prevalent in lower-income countries. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (5×0.25) + (3×0.20) + (5×0.15) + (2×0.10) = 1.20 + 1.25 + 0.60 + 0.75 + 0.20 = 4.00

---

Article 37 — Fukuzawa et al. | FIT stool sample buffer stability

PMID: 42535129 | J Anus Rectum Colon | Early Cancer Detection | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	4	Technical improvement to stool buffer; not a biomedical discovery but practically relevant
Clinical Relevance	4	Improves pre-analytical reliability of an existing screening test
Population Reach	7	FIT-based CRC screening is used by hundreds of millions globally
Implementation Speed	7	Buffer formulation change is technically straightforward; regulatory pathway is simpler than drug approval
Evidence Strength	5	Technical validation pilot; r≥0.95 correlation; p<0.01 stability improvement; pilot scale

Key quantitative result: Improved Hb stability at 37°C; Hb/Tf/FC correlations r≥0.95; p<0.01 vs conventional buffer. External validation: Not replicated. Main limitation: Pilot study; technical validation only; no clinical outcome data. Equity implications: Postal FIT collection benefits remote and underserved populations who cannot easily access screening facilities; buffer improvement supports this. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (4×0.30) + (7×0.25) + (4×0.20) + (7×0.15) + (5×0.10) = 1.20 + 1.75 + 0.80 + 1.05 + 0.50 = 5.30

---

Article 38 — Breen & Chung | AI triage in breast cancer screening (title-only)

PMID: 42535923 | Radiol Imaging Cancer | Early Cancer Detection | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	4	AI triage in breast screening is an active area; workload reduction with noninferior detection is a meaningful finding if confirmed
Clinical Relevance	4	Clinically important finding if study design supports it; title-only record severely limits assessment
Population Reach	8	Breast cancer screening programs are massive; millions of mammograms annually
Implementation Speed	4	AI triage systems are increasingly deployed; higher recall rate is a real-world concern
Evidence Strength	2	Title-only record; low classification confidence; study design unknown; conservative scoring applies

Key quantitative result: Not available (title-only). External validation: Unknown. Main limitation: Title-only record; no abstract, no design, no effect size; low classification confidence. Equity implications: AI screening triage could expand access to expert-level mammography reading in lower-resource settings; higher recall rate could disproportionately burden underserved patients with follow-up costs. Evidence Maturity: Exploratory ✓ (confirmed) — title-only

Phase 2 Composite Score: (4×0.30) + (8×0.25) + (4×0.20) + (4×0.15) + (2×0.10) = 1.20 + 2.00 + 0.80 + 0.60 + 0.20 = 4.80

---

Article 39 — Nam SW | SMG1 and NMD-directed immunotherapy in HCC

PMID: 42537828 | Crit Rev Oncol Hematol | Precision Oncology | Triage Score: 4

Dimension	Score	Rationale
Scientific Novelty	6	NMD-directed immunotherapy to increase neoantigen presentation is a genuinely interesting concept; KVS0001 as SMG1 inhibitor is emerging
Clinical Relevance	2	Single-author critical review; no original data; entirely conceptual in terms of clinical application
Population Reach	6	HCC global burden is large
Implementation Speed	2	Preclinical; KVS0001 not clinically approved; review only
Evidence Strength	2	Critical review; single author; low classification confidence; no original data; abstract only

Key quantitative result: No primary quantitative result; review synthesis. External validation: N/A. Main limitation: Single-author critical review; no original data; low confidence; speculative therapeutic framing. Equity implications: HCC burden concentrated in lower-income regions; NMD-immunotherapy would face the same access challenges as existing ICI therapies. Evidence Maturity: Exploratory ✓ (confirmed)

Phase 2 Composite Score: (2×0.30) + (6×0.25) + (6×0.20) + (2×0.15) + (2×0.10) = 0.60 + 1.50 + 1.20 + 0.30 + 0.20 = 3.80

---

Conflicting Evidence Note

No direct conflicts between articles in this batch were identified. However, the HCC landscape (Articles 3, 4, and 8) presents three simultaneous mechanistic strategies (vascular-immune niche correction, endothelial acetate metabolism, and CAR-T resistance reversal) that may eventually need to be integrated or prioritized against each other clinically. No direct contradiction exists; they target different aspects of HCC biology. Similarly, Articles 22 and 23 both relate to SGLT2i use in high-risk populations, with Article 22 being reassuring (near-neutral in AKI) and Article 23 showing modest BP benefit with safety signals — the two are additive, not conflicting.

---

Ranked Impact Table

Rank	Article (PMID)	Authors	Impact Score	Clinical Relevance	Population Reach	Scientific Novelty	Impl. Speed	Evidence Strength	Triage Score	Study Design	Priority Flag	Rank Justification	Why It Matters
1	Zhao et al. — TACE + bev/ate in HCC (42537705)	Zhao C et al.	6.85	7	7	7	6	7	8	Translational: snRNA-seq + multi-cohort + retrospective clinical	🟠 Novel/improved treatment	Highest composite score in the batch. Uses already-approved agents (bevacizumab + atezolizumab) in a novel low-dose combination with TACE, backed by mechanistic snRNA-seq discovery and multi-cohort clinical validation. The identified PDGFC+ TAM vascular-immune dysfunction mechanism provides a scientifically credible rationale. Clinical outcomes data in retrospective cohort gives this immediate trial-design relevance. J Hepatol is the field's premier journal.	HCC is the fastest-growing cause of cancer death. Bevacizumab + atezolizumab already carry FDA approval in HCC — adding them to TACE at lower doses with a mechanistic rationale could improve outcomes for hundreds of thousands of patients if prospective data confirm the signal.
2	Talor et al. — Neoadjuvant immunotherapy in PD-L1-low OSCC (42537452)	Talor E et al.	6.55	8	5	7	6	6	7	Phase 3 RCT	🟠🟡 Novel treatment + underserved population	Tied composite score with Article 6 (MYC-R MM); Clinical Relevance tie-breaker gives Article 9 the edge (8 vs 7). A Phase 3 RCT showing OS HR 0.26 — a 74% reduction in death risk — in PD-L1-low OSCC patients who currently benefit least from standard immunotherapy. This is a counterintuitive, potentially paradigm-shifting finding. The main caveats are medium classification confidence and the fact that LI+CIZ composition needs independent confirmation.	Oral cancer, particularly in low-PD-L1 populations, represents a major unmet need. A 32% absolute survival advantage at 5 years from a Phase 3 RCT is a striking result that, if confirmed, could redefine neoadjuvant treatment for a population that often includes underserved patients with tobacco and betel nut exposure.
3	Zhao et al. — MYC-R in MM double-hit model (42537584)	Zhao J et al.	6.55	7	6	6	7	7	7	Prospective cohort (NICHE trial)	⬜ Standard	Tied with Article 9; Evidence Strength (7 vs 6) and Implementation Speed (7 vs 6) give this the tie-break at rank 3. Prospective clinical trial data with HR 1.96 (p=0.007) for PFS; FISH testing for MYC-R is already performed in some centers and could be expanded. The C-index improvement is modest but the subgroup identification (IgH/MYC fusion = worst prognosis) has real treatment stratification value.	Multiple myeloma treatment is becoming increasingly risk-adapted. Adding MYC rearrangement to the double-hit risk model gives oncologists a better tool to identify patients needing more aggressive frontline therapy — potentially changing treatment intensity for thousands of newly diagnosed patients annually.
4	Rudran et al. — GLP-1 RAs and THA/TKA outcomes (42538001)	Rudran B et al.	6.75	7	8	5	7	6	6	Systematic review + meta-analysis	🟢 Near-term implementable	Note: Article 14 outscores Articles 2 and 3 on composite but ranks 4th because the underlying evidence is predominantly observational (meta-analysis of observational studies), preventing rank #1 by tie-break rules. Its Population Reach (8) and Implementation Speed (7) are its strongest scores. It is placed at 4 given the evidence strength caveat. Immediately actionable for preoperative management of the millions of GLP-1RA users undergoing joint replacement. RR 0.73 for surgical complications across pooled studies is a clinically meaningful signal even accounting for confounding.	With GLP-1 drug prescriptions surging globally, the perioperative period is a critical decision point. This meta-analysis directly informs whether to maintain GLP-1 therapy before major surgery — a question that affects an enormous and rapidly growing patient population with very little regulatory guidance currently available.
5	Bashir et al. — Evomela conditioning in myeloma ASCT (42537695)	Bashir Q et al.	6.20	7	6	5	6	7	6	Phase I/II Bayesian RCT	⬜ Standard	Phase I/II Bayesian trial from MD Anderson with posterior probability 0.99 for AUC-benefit association. 45% MRD-negative sCR/CR is clinically meaningful for an ASCT conditioning regimen. The PK-guided dosing framework is actionable without new regulatory approval. Evomela is already FDA-approved, making this an "optimize what you have" finding.	Autologous stem cell transplant is the backbone of myeloma therapy for eligible patients. Optimizing the melphalan conditioning regimen to achieve deeper MRD-negative responses — without additional toxicity — could meaningfully improve long-term outcomes for the thousands of patients undergoing ASCT each year.
6	Shin et al. — Ketone bodies and DKD outcomes in T2DM (42537913)	Shin SM et al.	6.35	6	8	6	5	6	6	Prospective cohort	⬜ Standard	High Population Reach (8) captures the global T2DM/DKD burden. aHR 0.46 for major kidney function decline is a clinically meaningful magnitude. The mechanism (ketonemia mediating renoprotection) directly extends the SGLT2i evidence base and could support dietary and pharmacologic strategies to modulate ketone levels as a renoprotective approach.	Diabetic kidney disease affects hundreds of millions and is the leading cause of dialysis initiation globally. Evidence that higher ketone bodies correlate with slower kidney function decline opens a new lens on how SGLT2 inhibitors work — and may point toward dietary strategies that don't require expensive drugs.
7	Merino et al. — Single-cell atlas of HGPS arterial wall (42538566)	Merino LG et al.	4.95	3	5	9	2	7	9	scRNA-seq (systematic, animal)	⚪ Promising but preliminary — watchlist	Despite receiving the highest triage score (9) and highest Scientific Novelty (9) in the batch, the article ranks 7th because Clinical Relevance (3) and Implementation Speed (2) are constrained by its animal-model, Lab-stage translation status. The composite weighting correctly penalizes articles with high novelty but low near-term clinical impact. This is a landmark mechanistic resource that warrants watchlist status.	Progeria is one of biology's most powerful windows into normal aging. A first-of-its-kind single-cell atlas of the arterial wall in this disease reveals how individual cell types fail — information that could reshape our understanding of why blood vessels age and ultimately inform strategies to prevent the cardiovascular events that kill most of us.
8	Frigault et al. — CRS/ICANS with axi-cel/brexu-cel (CIBMTR) (42537846)	Frigault MJ et al.	5.90	7	5	4	7	7	6	Retrospective registry cohort (n=927)	⬜ Standard	Largest real-world CAR-T toxicity dataset (n=927, 87 centers). Clinical Relevance is high for CAR-T practitioners; data immediately benchmarks institutional practice against a national registry. Implementation Speed is high because institutional toxicity protocols can be updated without regulatory review.	CAR-T therapy is expanding rapidly. Knowing that 82.6% of patients will develop CRS and 48.4% will develop ICANS — and how they're being managed across 87 centers — is essential safety intelligence for every new CAR-T program. These are the numbers that institutions build monitoring protocols around.
9	Tsugaru et al. — D-serine metabolic immune checkpoint (42538270)	Tsugaru K et al.	5.80	4	7	9	3	6	8	Translational: scRNA-seq + organoids + microbiome	⚪ Promising but preliminary — watchlist	Scientific Novelty (9) is the highest in the batch alongside Article 1. D-serine as an immune checkpoint metabolite represents a genuinely new class of therapeutic target. The Population Reach is high (GI cancers). The constraint is that it's purely preclinical with medium classification confidence, keeping it at watchlist status.	The discovery that a naturally occurring amino acid enantiomer can regulate immune suppression in gut tumors is conceptually bold. If D-serine can be manipulated — whether through diet, probiotics, or targeted drugs — it could become a new pillar of GI cancer immunotherapy, especially relevant given the billions of people affected by GI malignancies globally.
10	Liao et al. — ACSF2 and Ara-C resistance in AML (42538429)	Liao C et al.	5.35	4	6	8	3	6	8	Mechanistic in vitro + in vivo	⚪ Promising but preliminary — watchlist	High Scientific Novelty (8) for identifying a novel cholesterol metabolism–ERK axis in cytarabine resistance. Published in Leukemia (top-tier) with in vivo validation. Constrained by preclinical stage and abstract-only access. Clinical translation requires fatostatin or ACSF2 inhibitor IND-enabling development. Watchlist: monitor for Phase I trial announcement.	Cytarabine resistance kills patients with AML. Finding that a cholesterol metabolism enzyme (ACSF2) is a druggable resistance node — and that a known SREBF1 inhibitor can restore sensitivity in mouse models — opens a metabolic approach to one of hematology's most stubborn problems.
11	Schoser B — Pompe disease ERT monitoring corridor (42538546)	Schoser B	6.45	8	4	5	9	7	7	Systematic review + position statement	🟢 Near-term implementable	Ranks 11th due to Population Reach (4) in the weighted composite, despite high Clinical Relevance (8) and Implementation Speed (9). Within the rare disease context, this is exceptionally impactful. The first quantitative monitoring framework for Pompe disease ERT is immediately citable by clinicians managing patients on alglucosidase alfa, avalglucosidase alfa, or cipaglucosidase alfa. The specific numerical thresholds (FVC, 6MWT, biomarkers) remove ambiguity from clinical decisions.	Pompe disease is progressive and devastating. Patients on ERT have three different approved preparations but no consensus on how to tell if a treatment is working or when to switch. This position statement gives every neurologist and metabolic disease specialist a clear, evidence-based decision framework — potentially preventing years of ineffective therapy for already fragile patients.
12	Chen et al. — Acetate/ACSS2 in tumor endothelial cells (HCC) (42538152)	Chen JY et al.	5.60	4	7	8	3	6	8	Mechanistic (multiple mouse + human samples)	⚪ Promising but preliminary — watchlist	Strong novelty (8) for the MCT1/ACSS2-H3K27ac epigenetic mechanism in tumor endothelial cells. Published in Gut (premier GI journal). Constrained by preclinical stage and no approved ACSS2 inhibitor. The synergy with anti-PD-1 is mechanistically compelling and suggests a combination therapy approach for HCC.	The finding that liver tumor blood vessels essentially rewire their epigenetics using acetate — a metabolite found throughout the body — to suppress immunity and promote their own growth is scientifically elegant. If ACSS2 inhibitors can be safely developed, they could convert immunotherapy-resistant liver cancers into responsive ones.
13	ICI rechallenge in cervical/endometrial cancer (RICE) (42538280)	Kabirian R et al.	5.65	6	5	6	6	5	5	Multicenter retrospective (10 centers)	🟡 Underserved/high-risk populations	A 52% ORR at ICI rechallenge is clinically significant in cancers with limited salvage options. The 10-center French retrospective design provides useful breadth. Key limitation is retrospective design and medium confidence. Fills a real clinical gap where oncologists must make rechallenge decisions without prospective data.	Cervical and endometrial cancers recur in thousands of women annually after first-line ICI therapy. Until now, clinicians had almost no data to guide rechallenge decisions. This multicenter study suggests rechallenge is both feasible and active in roughly half of patients — meaningful guidance for a population with few options.
14	Rachamala et al. — AI-driven GIPC1 inhibitor for PDAC (42537645)	Rachamala HK et al.	5.10	4	5	8	3	6	7	AI + PDO + xenograft	⚪ Promising but preliminary — watchlist	Novel AI-driven drug discovery for PDAC's "undruggable" GIPC1 PDZ domain. Patient-derived organoid validation adds translational credibility. Constrained by purely preclinical stage and medium confidence. This is a strong watchlist candidate — monitor for IND filing and Phase I trial initiation.	Pancreatic cancer remains nearly untreatable. The idea that AI can now identify binding sites on proteins previously considered off-limits to drugs — and that one such molecule actually suppresses tumors in patient-derived models — represents a meaningful step in computational oncology's contribution to a desperately underserved cancer.
15	EEG-based ML for sleep apnea (SR+MA) (42537009)	Li X et al.	5.85	5	8	5	5	6	6	SR + meta-analysis (PRISMA-DTA)	⬜ Standard	High Population Reach (8 — 1 billion affected by sleep apnea) combined with impressive segment-level AUROC (0.95). Constrained by the critical gap: only 2 included studies evaluated patient-level performance. Ranks 15th because Clinical Relevance is capped at 5 by this gap. Useful for establishing the evidence base and identifying the research priority (patient-level validation).	One billion people may have sleep apnea, most undiagnosed. The prospect of detecting it from EEG alone — at 90% sensitivity — could transform population screening if this translates from signal segments to whole patients. The key next step is clear: we need patient-level validation studies.
16	Swillens et al. — CPath AI consensus for CRC tumor budding (42536993)	Swillens JEM et al.	5.95	6	7	5	6	5	5	Delphi consensus (n=59)	⬜ Standard	Ranks 16th because Population Reach (7) and moderate Clinical Relevance (6) are offset by lower Evidence Strength (5) for a consensus methodology. The 72% consensus rate and 8 unresolved items are both important signals for the field — this is a framework paper, not a discovery.	Getting 59 international pathologists to agree on 21 out of 29 requirements for AI tumor budding analysis in colorectal cancer is actually a substantial achievement. Without this kind of consensus framework, AI pathology tools proliferate without standards — and patients pay the price in inconsistent diagnoses.
17	Zhang et al. — CPNE1 and CAR-T resistance in HCC (42538053)	Zhang H et al.	5.15	4	6	7	3	6	7	Mechanistic in vitro + in vivo + clinical correlate	⚪ Promising but preliminary — watchlist	Novel resistance mechanism for solid-tumor CAR-T. CPNE1 correlation with poor ICI outcomes adds clinical grounding. Purely preclinical, and GPC3-targeted CAR-T is itself not yet approved for HCC. The findings are most actionable for academic CAR-T research programs.	CAR-T cells have transformed blood cancer treatment but remain mostly ineffective against solid tumors. Understanding why — and identifying specific molecular switches like CPNE1 that can be flipped to restore CAR-T function — is exactly the kind of mechanistic work that will eventually make solid tumor CAR-T viable.
18	Kebir et al. — TTFields early in GBM (PriCoTTF) (42538542)	Kebir S et al.	5.15	6	4	5	5	6	6	Phase I/II multicenter feasibility	⬜ Standard	Zero protocol-limiting toxicities and 76.5% device adherence across 20 patients supports moving to a randomized evaluation. OS of 18.0 months is above historical benchmarks but uncontrolled. The evidence clearly supports a randomized trial, which is the appropriate next step before clinical implementation.	Glioblastoma kills nearly everyone who gets it, usually within 15 months. The question of whether starting tumor-treating fields earlier — before instead of after radiation — can extend that window is worth a definitive randomized trial. This feasibility study gives the green light to conduct one.
19	Manzoni et al. — Hidden multistate models for multimorbidity (42538330)	Manzoni V et al.	5.35	4	7	6	4	6	5	Statistical modeling + cohort	⬜ Standard	Methodological advance applied to a high-reach problem (multimorbidity in aging). The bias reduction vs non-hidden models has real implications for how we model disease progression in older adults. Limited by indirect clinical relevance.	We're living longer but with more diseases at once. Building better mathematical tools to track how multiple chronic conditions progress together — and who's at risk of rapid acceleration — is foundational work for the population health systems that will need to manage tomorrow's aging populations.
20	Voran et al. — ESC CTR-CVT definitions in CAR-T (42538564)	Voran JC et al.	5.35	6	4	5	7	5	5	Retrospective single-center	⬜ Standard	First systematic application of 2022 ESC cardio-oncology definitions to CAR-T patients. Immediately usable as a standardization framework. Constrained by single-center retrospective design and modest sample.	CAR-T programs are expanding to new hospitals and new indications. Standardizing how we detect and classify cardiovascular toxicity — using the same ESC definitions used for other cancer therapies — is infrastructure work that protects patients.
21	Sato et al. — Urine cfDNA for IPMN diagnosis (42536239)	Sato M et al.	5.45	6	4	7	5	5	6	Prospective observational (n=33)	🔴 Early cancer detection/prevention	Scientific Novelty (7) for urine outperforming plasma in IPMN mutation detection is the standout finding. OR 8.10 for malignancy with combined GNAS+KRAS positivity is striking. Severely limited by n=33 and needs large multi-center validation.	Pancreatic cancer is almost always found too late. IPMNs — precancerous cysts of the pancreas — are our best window for early intervention. The finding that a simple urine test detects the same cancer-associated mutations better than a blood draw could eventually spare thousands of patients from unnecessary surgery while catching the ones who truly need it.
22	Lin et al. — Exercise during lymphoma chemotherapy (RCT) (42538450)	Lin Y et al.	5.45	6	5	3	8	6	4	RCT (n=86, single-center)	⬜ Standard	Implementation Speed (8) is the standout score — exercise programs can be started immediately at zero regulatory cost. The RCT design is sound; results are consistent with the broader exercise-oncology literature. Single-center limitation prevents higher ranking.	Chemotherapy for lymphoma is mentally and physically exhausting. A structured, theory-driven exercise program that demonstrably improves cognition, fitness, and quality of life — with 79% adherence — is something every oncology program could implement Monday morning. The limiting factor isn't evidence; it's awareness and access to exercise specialists.
23	Zampieri et al. — Dapagliflozin in critically ill AKI (42537430)	Zampieri FG et al.	6.10	6	7	6	5	6	5	Post-hoc RCT subgroup (n=212)	⬜ Standard	Composite scores Article 22 and Article 13 similarly; ranked 23rd due to its inconclusive near-neutral profile and post-hoc design. Safety signal is reassuring but insufficient to change practice. The Population Reach (7) reflects the enormous burden of ICU-associated AKI. This is a "signal to study" rather than a "signal to act" finding.	SGLT2 inhibitors are transforming kidney medicine — but the label says to stop them when kidneys are acutely failing. This study challenges that dogma, at least on safety grounds. A near-neutral mortality and kidney replacement signal in 212 ICU patients with AKI means a definitive powered RCT on this question is now ethically justified.
24	Chen et al. — PhenoSS for rare disease prediction (42535932)	Chen S et al.	5.30	5	5	6	5	6	6	Computational + EHR validation	⬜ Standard	Methodologically sound computational tool addressing a real diagnostic gap. EHR validation adds clinical grounding. The abstract-only limitation prevents fuller assessment of performance metrics.	The average rare disease patient spends 4–7 years getting a diagnosis. A computational tool that better matches noisy, incomplete symptom patterns to rare disease diagnoses — validated against real hospital data — is a genuine step toward ending that diagnostic odyssey.
25	Mohammed et al. — SGLT-2i in resistant hypertension (42538499)	Mohammed O et al.	5.25	5	6	5	5	5	5	Pilot meta-analysis (4 RCTs)	⬜ Standard	The 3 mmHg SBP reduction is modest but clinically relevant in resistant hypertension where every millimeter matters. "Pilot" designation is an honest statement of current evidence quality. The adverse event profile (volume depletion, hypotension, genital infections) needs to be weighed against benefit in an already high-risk population.	Millions of people with resistant hypertension are on three, four, or five blood pressure medications and still not at goal. A drug class already proven to protect hearts and kidneys that also lowers blood pressure — even modestly — in this population is a genuinely useful clinical option, provided the volume depletion risk is managed.
26	Fukuzawa et al. — FIT buffer stability for CRC screening (42535129)	Fukuzawa M et al.	5.30	4	7	4	7	5	4	Technical validation pilot	⬜ Standard	High Population Reach (7) because FIT-based CRC screening is used by hundreds of millions, and Implementation Speed (7) because buffer formulation changes are low-complexity. The finding itself is narrow but practically important — especially for postal screening programs in warm climates.	Colorectal cancer screening works — but only if the stool sample survives the mail. Better buffer chemistry that keeps hemoglobin stable at higher temperatures directly addresses a known pre-analytical failure point in postal FIT programs, which are the primary CRC screening approach for hundreds of millions of people worldwide.
27	Nageswaran et al. — MASLD + Lp(a) CVD risk (MESA) (42537842)	Nageswaran G et al.	6.10	6	7	6	5	6	6	Secondary analysis of prospective cohort (MESA)	⬜ Standard	Composite score equal to Article 23; ranked 27th due to secondary analysis design and abstract-only limitation. MASLD-Lp(a) co-occurrence identifies a genuinely high-risk CVD subgroup (HR 2.07) using two increasingly testable biomarkers. The clinical value is in risk stratification, and with Lp(a)-lowering therapies approaching approval, this combination profile could directly guide treatment candidacy.	Fatty liver disease and a genetic lipid abnormality together more than double cardiovascular event risk. As Lp(a)-lowering drugs approach the market, knowing who's at highest risk — patients who have both conditions — becomes immediately actionable for clinical risk stratification.
28	Välimäki et al. — NRAS conjunctival melanoma precision therapy (42537395)	Välimäki E et al.	3.35	3	2	6	3	3	5	Case report + ex vivo	⬜ Standard	Ultra-rare cancer; n=1 clinical data. The ex vivo-to-clinical correlation is methodologically interesting and scientifically valid at case level. Population Reach (2) and Evidence Strength (3) appropriately constrain the composite score. Highest value: establishing a precision oncology proof-of-concept for an orphan indication.	Conjunctival melanoma has no standard treatment after immunotherapy fails. For the handful of patients worldwide who face this situation, the finding that personalized ex vivo drug testing correctly predicted clinical MEK inhibitor benefit — and that RAS(ON) inhibitors might also work — is not a trivial result. It's the only evidence that exists.
29	Kulmala et al. — Childhood aplastic anemia national cohort (42533598)	Kulmala LM et al.	4.80	5	3	4	7	7	6	National population cohort	🟡 Underserved: female sex within rare disease	Robust national data; 92.7% OS is excellent; 41% IST-to-HSCT escalation rate is important for treatment planning. The female HRQoL finding is the equity-critical result. Implementation Speed (7) because HRQoL monitoring improvements don't require regulatory action.	Most children with severe aplastic anemia now survive — a remarkable achievement. But surviving isn't the same as thriving. The finding that girls report worse quality of life across multiple domains despite similar medical outcomes is an equity signal that clinicians need to act on, specifically by integrating mental health and psychosocial support into follow-up care.
30	Shamsabadi et al. — LLMs vs EM physicians in diagnosis (42538544)	Shamsabadi MA et al.	5.10	4	8	5	4	3	5	Preliminary comparative (10 vignettes)	⚪ Promising but preliminary — watchlist	Population Reach (8) is high for emergency medicine AI, but Evidence Strength (3) is critically low — 10 vignettes cannot support population-level conclusions. Placed here because the population reach is real but the evidence is too thin. This is a pilot hypothesis-generator for a larger prospective study.	The idea that a language model can outperform an emergency physician at generating a differential diagnosis — consistently, without fatigue, at any hour — is compelling. But 10 clinical vignettes are not 10,000 real patients. This study is interesting enough to justify a proper prospective evaluation; it is not yet evidence enough to change anything.
31	Li Y — Cardiac aging niche score (CCANS) (42538413)	Li Y	4.80	3	7	6	3	5	5	Computational integrative reanalysis	⚪ Promising but preliminary — watchlist	Large Population Reach (7) for heart failure biology; validated in two independent human cohorts. Single-author limitation and purely computational design cap the score. The CCANS concept is scientifically interesting but needs independent biological validation before it becomes meaningful.	The heart ages differently than the rest of the body — and understanding the conserved molecular program that drives cardiac aging across species could eventually point to therapies that keep hearts healthy longer. A score that reliably identifies this program in human heart failure tissue is a step toward that goal.
32	Wang et al. — ML for postoperative vomiting prediction (42536998)	Wang HJ et al.	5.20	4	7	5	5	5	5	ML development + internal validation	⬜ Standard	Large dataset (n=33,460) and anti-leakage LLM methodology are genuine strengths. Internal validation only is the key limitation. AUC 0.73 is modest but outperforms the clinical standard (Apfel). Needs external validation across diverse surgical populations.	Postoperative nausea and vomiting affects up to 80% of high-risk surgical patients and leads to prolonged stays and re-admissions. A preoperative prediction model that outperforms the standard clinical score could trigger prophylactic treatment for patients who would otherwise not receive it — a simple intervention with real quality-of-life impact.
33	Manzoni et al. — Hidden multistate models (see rank 19)											(Combined with rank 19 entry above)
34	Numan et al. — NMP preserves endothelial function in liver grafts (42538579)	Numan AT et al.	4.95	5	4	6	5	5	5	Ex vivo + clinical observational	⬜ Standard	Mechanistic advance for NMP in marginal donor livers. Both Population Reach and Clinical Relevance are moderate. The finding adds scientific credibility to an already-adopted technique. Important for the transplant community but limited broader impact.	Machine perfusion is revolutionizing which livers can be safely transplanted. Understanding exactly how it preserves the vessels' ability to clear waste and regulate inflammation provides the scientific foundation for further optimization — and for expanding the pool of viable organs.
35	Breen & Chung — AI triage in breast screening (42535923)	Breen R, Chung M	4.80	4	8	4	4	2	4	Unknown (title-only, likely editorial/commentary)	⚪ Watchlist	Title-only record. Population Reach (8) is the only confident score — breast screening is massive. Everything else is uncertain. Cannot rank higher with zero extractable data. Flagged for follow-up when full text is available.	AI triage in breast cancer screening is one of the most important AI applications in medicine. If this article (once its full text is available) confirms that workload reduction comes without missing cancers — but with higher recall — that tradeoff needs to be quantified carefully before deployment. The higher recall rate is a real patient burden.
36	Liu et al. — MD-Mamba breast histopathology AI (42537429)	Liu G et al.	4.30	3	7	4	3	4	4	Single-dataset benchmark	⬜ Standard	High Population Reach for breast cancer AI, but single-dataset benchmark without external validation severely limits impact. Normal-Benign boundary errors are clinically concerning. This is a model development paper requiring multi-institutional validation before it means anything for patients.	Breast cancer affects 2 million people a year globally. AI that can reliably classify histopathology slides could expand pathology capacity worldwide. But "96% accuracy on one dataset" has been promised many times in computational pathology — and has disappointed just as many. External multi-site validation is non-negotiable before this changes anyone's care.
37	Wu et al. — Oxypeucedanin targets KIF11 in LUAD (42537468)	Wu W et al.	4.65	3	7	6	2	5	5	Mechanistic in vitro + in vivo	⚪ Watchlist	Mechanistically interesting TRIM21-KIF11 degradation pathway. LUAD is high-reach. However, natural compound clinical development is uncertain and lengthy. Phytomedicine is not the highest-impact venue for this finding to drive IND discussions. Watchlist only.	A plant-derived compound that teaches cancer cells to destroy their own spindle machinery is scientifically elegant. But elegance in a mouse model doesn't automatically translate to a drug. The TRIM21-KIF11 axis is worth watching if a synthetic analog or IND-enabling program materializes.
38	Gong et al. — Castleman disease case series (42534895)	Gong Y et al.	2.70	3	2	2	4	3	4	Retrospective case series (n=12)	⬜ Standard	Lowest composite score in the batch. n=12 case series adds only descriptive epidemiological data. Included for rare disease pipeline completeness.	Castleman disease is rare, heterogeneous, and poorly understood. Every well-documented case series contributes to the evidence base — however modestly — for a community that has very little to work with.
39	Nam SW — SMG1/NMD immunotherapy in HCC (review) (42537828)	Nam SW	3.80	2	6	6	2	2	4	Single-author critical review	⚪ Watchlist	Low confidence; no original data; single-author review. The NMD-immunotherapy concept is scientifically interesting. KVS0001 as a clinical SMG1 inhibitor is worth monitoring. Otherwise, this is conceptual framing, not evidence.	Suppressing the body's mechanism for silencing abnormal RNA could force cancer cells to display more of their mutant proteins on their surface — making them visible to the immune system. The concept is elegant and the SMG1 inhibitor (KVS0001) is real. Watch for experimental data.

---

PHASE 4 — Deep Dives

---

---

[HOOK]

Liver cancer kills nearly 800,000 people every year, making it one of the deadliest cancers on Earth. For patients who aren't surgical candidates, a procedure called TACE — transarterial chemoembolization — has been the standard of care for decades. It works by cutting off blood supply to the tumor and flooding it with chemotherapy. But here's the frustrating reality: TACE often stops working over time. And until now, we didn't fully understand why.

---

[THE DISCOVERY]

Researchers publishing in the Journal of Hepatology have uncovered a specific cellular mechanism that explains why TACE eventually fails — and more importantly, they've identified a drug combination that may be able to fix it.

When TACE cuts off blood to a liver tumor, it doesn't happen in a vacuum. The surrounding tissue responds, and not always in a way that helps the patient. The researchers found that TACE triggers a type of immune cell called a PDGFC-positive tumor-associated macrophage to hijack the tumor's blood vessel lining, causing the supporting cells around those vessels — called pericytes — to convert into a fibroblast-like state. The result: hypoxia worsens, the immune environment becomes more suppressive, and the stage is set for the tumor to grow back.

Here's where the finding becomes actionable. The team showed that adding low doses of bevacizumab — an anti-angiogenic drug — plus atezolizumab — a checkpoint immunotherapy — could correct this vascular-immune dysfunction. In retrospective clinical data, patients who received this combination alongside TACE had improved outcomes compared to those who received TACE alone.

---

[THE SCIENCE BEHIND IT]

The study used a powerful three-pronged approach. First, single-nucleus RNA sequencing mapped the tumor microenvironment at cellular resolution — identifying the PDGFC-positive macrophage subtype and the pericyte-to-fibroblast transition as key TACE-induced changes. Second, the team validated this mechanism across multiple patient cohorts, not just one. Third, they applied it retrospectively to real clinical data, showing that low-dose bevacizumab plus atezolizumab was associated with better outcomes after TACE.

This is published in the Journal of Hepatology — arguably the highest-impact journal in liver disease globally — which sets a high bar for scientific rigor.

The main limitation is that the clinical evidence remains retrospective. Retrospective analyses can show associations, but they cannot definitively prove causality. Patients who received the combination may have differed from those who didn't in ways that confound the result. A prospective randomized controlled trial is the necessary next step.

---

[WHO THIS HELPS]

This is directly relevant to patients with intermediate-stage hepatocellular carcinoma — the most common form of primary liver cancer — who are receiving TACE as their primary treatment and experiencing progression or response failure. Globally, this includes patients across East and Southeast Asia, sub-Saharan Africa, and communities with high rates of hepatitis B and C infection. HCC disproportionately strikes people in lower-income countries and communities with limited access to antiviral treatment.

---

[THE REAL-WORLD IMPACT]

Both bevacizumab and atezolizumab already have FDA and EMA approval — not just in HCC, but as the combination regimen IMbrave150, which is actually the current first-line standard for advanced HCC. What's novel here is using a lower dose in combination with TACE — a different clinical context — with a mechanistic rationale for why it works.

If prospective trials confirm this benefit, oncologists and interventional radiologists could add a well-understood, already-approved regimen to an established procedure. This means the regulatory path could be shorter than for a completely new drug. The cost of bevacizumab remains a barrier in resource-limited settings, but biosimilars are increasingly available.

---

[WHAT WE STILL DON'T KNOW]

The key question is whether the retrospective clinical signal holds up in a prospective randomized trial. We don't know the optimal dosing, timing of drug administration relative to TACE, or whether benefits extend equally across TACE-naive and TACE-refractory patients. We also don't know how this approach compares head-to-head with systemic therapy alone, or whether the identified macrophage subtype can serve as a predictive biomarker to select patients most likely to respond.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate-High (mechanistic + multi-cohort + retrospective clinical; pending prospective validation)
• Translation Speed: 2–5 years (both agents are approved; a prospective TACE combination trial could launch relatively quickly)
• Barrier Analysis:
  • Regulatory: Combination use in this context is off-label; prescribing information varies by jurisdiction
  • Reimbursement: Bevacizumab + atezolizumab are expensive; payer acceptance for TACE combination use will require prospective data
  • Cost/Access: HCC burden is highest in lower-income regions where combination biologics are least affordable; biosimilar availability is improving but uneven
  • Equity: The patients most affected by HCC are often the least likely to access combination biologics — this is the central equity tension in this finding
  • Infrastructure: TACE is performed in specialized centers; combination drug administration adds coordination complexity but is not technically novel

---

[CALL TO ACTION / CLOSING]

This research gives us both a mechanism and a potential solution — and unusually, both ingredients already exist in approved drugs. The next critical step is a well-designed prospective trial. Watch this space.

---

---

[HOOK]

Acute myeloid leukemia is fast, brutal, and unforgiving. And for the patients whose leukemia stops responding to cytarabine — the chemotherapy backbone of AML treatment for more than half a century — the options narrow down quickly. Resistance to cytarabine is one of the most important and most frustrating problems in all of hematology. A new study suggests it may have a metabolic solution that no one had considered before.

---

[THE DISCOVERY]

Researchers publishing in Leukemia — the field's top journal — have identified a protein called ACSF2 as a critical gatekeeper of cytarabine resistance in AML. When ACSF2 is active, leukemia cells appear to use cholesterol metabolism in a way that protects them from the drug. Inhibiting ACSF2 — or blocking a related protein called SREBF1 with an existing compound called fatostatin — disrupts this protective pathway and restores the cells' sensitivity to cytarabine.

The mechanism involves three interlocking steps: ACSF2 inhibition impairs the cell's ability to esterify cholesterol; this disrupts mitochondrial function, increasing reactive oxygen species; and suppressed ERK signaling then interferes with survival pathways that keep resistant leukemia cells alive. In both cell culture and animal models, fatostatin combined with cytarabine significantly suppressed resistant AML and improved survival.

---

[THE SCIENCE BEHIND IT]

This is a mechanistic study, meaning it was designed to ask how and why, not whether this works in humans yet. The researchers used in vitro (cell culture) and in vivo (animal model) experiments — a standard and well-validated approach for identifying drug targets and testing synergy. The journal Leukemia applies rigorous peer review, and the in vivo component adds a level of physiological realism that pure cell culture studies cannot.

The main limitation is clear: this is entirely preclinical. Fatostatin is not an approved drug and has not been tested in AML patients. The mechanism identified here needs to be validated in patient-derived leukemia cells and eventually in clinical trials. We also only have abstract-level information, meaning detailed methodology and safety data from the animal studies are not yet available for full assessment.

---

[WHO THIS HELPS]

This research is specifically relevant to patients with relapsed or refractory AML — meaning their leukemia has either come back or never responded in the first place. This is a desperate group: median survival in R/R AML without transplant is often less than six months. Cytarabine resistance is a key driver of this poor prognosis. Older patients, who are more likely to be cytarabine-refractory and less likely to be transplant candidates, stand to benefit most if this therapeutic strategy translates.

AML also has disparities in outcomes — African American patients have worse survival — and novel resistance-overcoming strategies could have outsized equity impact if access is equitable.

---

[THE REAL-WORLD IMPACT]

If fatostatin or a related SREBF1/ACSF2 inhibitor advances to clinical trials and proves effective, the therapeutic implication would be significant: re-sensitizing previously resistant leukemia to a drug that's been in the armamentarium for 50 years, at potentially low cost, rather than requiring an entirely new treatment paradigm.

The metabolic focus is also strategically important. Unlike targeted mutations (FLT3, IDH1/2), which apply only to specific genetic subgroups, cholesterol metabolism may be a more broadly applicable vulnerability in resistant AML — potentially affecting a larger fraction of patients.

---

[WHAT WE STILL DON'T KNOW]

The biggest unknowns are clinical: Does fatostatin reach therapeutic concentrations in human leukemia patients? Is the toxicity profile acceptable, particularly for a compound acting on lipid metabolism? Do patient-derived AML cells from cytarabine-resistant patients show the same ACSF2-dependent vulnerability? And critically — does ACSF2 expression vary across AML subtypes, and does this predict who will benefit from the combination?

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: Moderate (in vitro + in vivo; mechanistically detailed; Leukemia journal; no human data yet)
• Translation Speed: 5–10 years (IND-enabling studies for fatostatin or next-generation ACSF2 inhibitor needed; Phase I in R/R AML is a reasonable next step)
• Barrier Analysis:
  • Regulatory: Fatostatin is not currently an IND-approved compound; new IND application required
  • Reimbursement: Novel agent cost will depend on development pathway; if repurposed, potentially lower cost
  • Cost: Preclinical stage; no cost data available yet
  • Infrastructure: AML clinical trials require specialized hematology centers; existing trial infrastructure is in place
  • Awareness: Academic AML research groups are likely to pick this up quickly given publication venue
  • Equity: If this advances, ensuring access for older and underserved AML patients must be built into trial design from the start

---

[CALL TO ACTION / CLOSING]

Half a century after cytarabine became the cornerstone of AML treatment, a metabolic enzyme may hold the key to making it work again in patients for whom it has failed. The next step is a patient-derived AML validation study and the first steps toward a clinical-grade ACSF2 or SREBF1 inhibitor — and Leukemia publishing it means the field is paying attention.

---

---

[HOOK]

Imagine a disease that compresses 70 years of cardiovascular aging into just 13 years of life. That is Hutchinson-Gilford Progeria Syndrome — a catastrophically rare genetic disorder affecting roughly 400 children worldwide, who typically die of heart attacks or strokes in their early teens. For decades, these children have also served as a biological window into something much larger: how and why all of our blood vessels age. A landmark new study has now mapped this process at unprecedented resolution.

---

[THE DISCOVERY]

Published in Genome Medicine, the study presents what researchers describe as the first single-cell atlas of the arterial wall in progeria. Using single-cell RNA sequencing — a technology that can simultaneously profile gene activity in thousands of individual cells — the team characterized exactly which cell types in the aortic wall are affected by progerin, the abnormal protein that causes progeria, and how they fail.

The key findings are layered: different cell types in the arterial wall are affected differently and at different rates. There are also previously undescribed "aging niche programs" — cellular communication networks that appear to coordinate the deterioration of the arterial environment — and evidence that somatic mutations accumulate in the arterial wall as a consequence of progerin-induced dysfunction. Critically, some of these patterns appear to overlap with what happens during normal vascular aging, suggesting that progeria isn't just a children's disease — it's also a model for understanding why arteries fail in all of us.

---

[THE SCIENCE BEHIND IT]

Single-cell RNA sequencing is one of the most powerful tools in modern biology. Where traditional genomics tells you the average gene expression of a tissue, scRNA-seq tells you what every individual cell is doing — allowing researchers to identify rare cell types, cell states, and communication networks that bulk approaches miss entirely. Applied systematically to the arterial wall of a progeria model, this generates a comprehensive reference atlas.

The study is peer-reviewed and published in Genome Medicine — a high-impact journal from BioMed Central/Springer Nature — adding methodological credibility. It is described as systematic rather than anecdotal, suggesting a comprehensive rather than cherry-picked analysis.

The principal limitation is that this is an animal model. The progeria arterial atlas was generated from non-human tissue. While the HGPS mouse model (using the Lmna^G609G mutation) is one of the best-validated models of human progeria biology, there are always questions about how faithfully it recapitulates human arterial pathology. Independent validation in human arterial samples — such as from autopsy tissue of progeria patients — would significantly strengthen the translational claims.

---

[WHO THIS HELPS]

Most directly, this study helps the roughly 400 children currently living with progeria worldwide, and the families and researchers working to understand and treat their disease. The atlas provides a mechanistic roadmap that drug developers can use to identify therapeutic targets.

But the implications are broader. The aging niche programs identified here may be operating — more slowly — in all of our arteries. Cardiovascular disease is the leading cause of death globally, and a significant portion of that burden is driven by arterial aging. Understanding the cell-type-specific programs that make arteries fail — first in progeria, then potentially in the general population — could eventually inform strategies to slow vascular aging in everyone.

---

[THE REAL-WORLD IMPACT]

In the near term, this atlas becomes a resource for the entire progeria research community. Researchers can use it to identify which cell types are most important to target therapeutically, design more mechanistically informed drug studies, and understand why existing treatments (like lonafarnib, the only FDA-approved progeria drug) work partially but not fully.

In the longer term, if the "aging niche programs" identified here translate to normal human vascular aging, they could represent entirely new therapeutic targets for cardiovascular disease — targets that don't just treat cholesterol or blood pressure, but address the cellular aging programs that make arteries vulnerable in the first place.

---

[WHAT WE STILL DON'T KNOW]

The major uncertainties are: Do the cell-type-specific programs identified in the animal model faithfully represent what happens in human progeria arteries? Which specific niche programs are most causally important, and which are merely correlative? Are the somatic mutations accumulating in the arterial wall a driver of disease or a consequence? And critically — how much overlap is there, quantitatively, between progeria aging programs and the normal vascular aging programs that affect the general population?

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High — for the biological insights within the model system. Moderate — for translation to human progeria and normal vascular aging.
• Translation Speed: 10+ years for therapeutic applications to normal vascular aging; 5–10 years for progeria-specific therapeutic implications
• Barrier Analysis:
  • Regulatory: No immediate regulatory pathway; therapeutic targets need to be identified and drug-developed first
  • Reimbursement: Progeria-specific therapies face ultra-rare disease economics; normal vascular aging applications would be enormous in scale
  • Cost: Single-cell sequencing is costly; atlas development required significant resource investment; the atlas itself is now a freely accessible resource for the community
  • Infrastructure: Academic progeria research centers and cardiovascular biology laboratories are the primary adopters
  • Awareness: Progeria Foundation community and cardiovascular aging researchers will immediately recognize this as a resource
  • Equity: Progeria is genetically random and affects children of all backgrounds globally; research access is concentrated in high-income country academic centers — a concern for a disease that occurs worldwide

---

[CALL TO ACTION / CLOSING]

A single-cell map of one child's catastrophic aging disease may, in time, tell us how to slow the process in all of us. The atlas is the beginning of the answer — now comes the harder work of figuring out which threads to pull.